focus -WSS

focus

author：comprehensive 2025-09-06 04:30:26 - browse：8343

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： More regulation could be coming for drug ads

focus

WSS

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Can U.S. cancer drug shortages be fixed?

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Sage's campaign to raise awareness of postpartum depression hits a nerve

Zapping the brain for stroke rehab: Pivotal clinical trial begins

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Judge rejects Trump's counterclaim against E. Jean Carroll

Cancer drug shortages should be causing more outrage

Discs beat pads, tampons for heavy menstrual flow, new study shows

Psychedelics group wrestles with new pharma identity

CDC launches VaccineFinder tool to locate Covid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Judge rejects Trump's counterclaim against E. Jean Carroll

Bright Health sells Medicare Advantage business to Molina

‘The Bear’ and hospitality in hospitals

hotspot

PBMs are inflating the cost of generic drugs. They must be reined in

Former Pear Therapeutics executives start new VC firm

Germany receives 178 compensation applications from gay servicepeople over discrimination

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Astronauts get first look at the spacecraft that will fly them around the moon

FTX founder Sam Bankman

focus

hotspot

explore

focus